# AtriCure, Inc. (ATRC) insider trading

> In the 12 months to Nov 15, 2026, 9 ATRC insiders reported open-market sales of $5.1M across 18 filings; no open-market purchases were filed.

Canonical: https://massive.com/quote/atrc/insider-trading
Latest filing: 2026-11-10 (last 12 months; source: SEC EDGAR)
Source: Massive (https://massive.com/docs/llms.txt)

## Summary

| Measure | Value | Detail |
| --- | --- | --- |
| Open-market sales | $5.1M | 18 filings · 9 insiders |
| Open-market purchases | $0 | 0 filings |
| Pre-arranged sales (10b5-1) | 4 of 18 | $1.4M of $5.1M sold (28%) |

## Open-market trades by insider

| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
| --- | --- | --- | --- | --- | --- | --- |
| Salvatore Privitera | Chief Technical Officer | $1.4M | — | 4 | 100% of sales | 2026-11-05 |
| Sven Wehrwein | Director | $1.3M | — | 2 | — | 2026-07-30 |
| Vinayak Doraiswamy | Chief Scientific Officer | $523.1K | — | 3 | — | 2026-07-30 |
| Karl S. Dahlquist | Chief Legal Officer | $458.1K | — | 1 | — | 2026-08-26 |
| Justin J. Noznesky | Chief Mktg & Strategy Officer | $432.5K | — | 2 | — | 2026-07-30 |
| Regina E. Groves | Director | $288.1K | — | 1 | — | 2026-09-14 |
| Maggie Yuen | Director | $241.6K | — | 2 | — | 2026-08-07 |
| Karen Prange | Director | $224.2K | — | 2 | — | 2026-08-07 |
| B. Kristine Johnson | Director | $143.4K | — | 1 | — | 2026-11-10 |

## Open-market trades by filing

18 filings in the last 12 months, newest first.

| Filed | Traded | Insider | Role | Type | Shares | Avg price | Value | Held after | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2026-11-10 | 2026-11-06 | B. Kristine Johnson | Director | Sale | 2,452 | $58.48 | $143.4K | 53,502 | — |
| 2026-11-05 | 2026-11-04 | Salvatore Privitera | Chief Technical Officer | Sale (10b5-1) | 8,404 | $65.00 | $546.3K | 134,341 | — |
| 2026-09-24 | 2026-09-23 | Salvatore Privitera | Chief Technical Officer | Sale (10b5-1) | 4,519 | $60.00 | $271.1K | 142,745 | — |
| 2026-09-14 | 2026-09-11 | Regina E. Groves | Director | Sale | 5,313 | $54.22 | $288.1K | 34,546 | — |
| 2026-09-10 | 2026-09-08 | Salvatore Privitera | Chief Technical Officer | Sale (10b5-1) | 3,657 | $55.00 | $201.1K | 147,264 | — |
| 2026-09-04 | 2026-09-02 | Salvatore Privitera | Chief Technical Officer | Sale (10b5-1) | 7,763 | $52.50 | $407.6K | 150,921 | — |
| 2026-08-26 | 2026-08-24 | Karl S. Dahlquist | Chief Legal Officer | Sale | 9,370 | $48.89 | $458.1K | 87,319 | — |
| 2026-08-07 | 2026-08-05 | Karen Prange | Director | Sale | 3,564 | $38.80 | $138.3K | 22,809 | — |
| 2026-08-07 | 2026-08-05 | Maggie Yuen | Director | Sale | 3,500 | $38.42 | $134.5K | 14,015 | — |
| 2026-07-30 | 2026-07-28 | Sven Wehrwein | Director | Sale | 25,000 | $37.84 | $946.0K | 40,518 | — |
| 2026-07-30 | 2026-07-29 | Justin J. Noznesky | Chief Mktg & Strategy Officer | Sale | 6,182 | $38.80 | $239.9K | 100,219 | — |
| 2026-07-30 | 2026-07-28 | Vinayak Doraiswamy | Chief Scientific Officer | Sale | 6,000 | $38.88 | $233.3K | 86,511 | — |
| 2026-05-22 | 2026-05-20 | Karen Prange | Director | Sale | 3,000 | $28.65 | $86.0K | 26,373 | — |
| 2026-05-18 | 2026-05-15 | Vinayak Doraiswamy | Chief Scientific Officer | Sale | 5,000 | $28.13 | $140.7K | 91,875 | — |
| 2026-03-16 | 2026-03-12 | Vinayak Doraiswamy | Chief Scientific Officer | Sale | 5,000 | $29.83 | $149.2K | 96,875 | — |
| 2025-11-26 | 2025-11-24 | Sven Wehrwein | Director | Sale | 10,000 | $37.66 | $376.6K | 34,374 | — |
| 2025-11-26 | 2025-11-26 | Justin J. Noznesky | Chief Mktg & Strategy Officer | Sale | 5,166 | $37.29 | $192.6K | 78,798 | — |
| 2025-11-25 | 2025-11-21 | Maggie Yuen | Director | Sale | 3,000 | $35.72 | $107.2K | 11,371 | — |

## Other insider activity (not market trades)

- Option exercises: 4 records
- Tax withholding: 7 records
- Grants and awards: 28 records
- Gifts: 6 records

Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.

## How to read this page

- **Open-market purchase or sale**: A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- **Pre-arranged (10b5-1)**: The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- **Filing date**: Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.

## FAQ

### Has AtriCure, Inc.'s CEO sold stock?

No. Michael H. Carrel (CEO) made no open-market sales filed as CEO in the last 12 months.

### How current is ATRC’s insider data?

These are ATRC Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.

### What counts as an open-market buy or sell?

Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.

## Live data

This page joins two Massive endpoints: Form 4 filings and daily prices. The ATRC Form 4 request:

- `GET https://api.massive.com/stocks/filings/vX/form-4?tickers=ATRC&filing_date.gte=2025-11-15&sort=filing_date.desc&limit=500`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [AtriCure, Inc. (ATRC) stock price](https://massive.com/quote/atrc.md)
- [Recent insider trading](https://massive.com/quote/insider-trading.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
